Outcome of patients with acute myelogenous leukemia after second salvage therapy

Francis GilesHagop Kantarjian


Although the prognosis is poor for patients with acute myelogenous leukemia (AML) who have disease recurrence after frontline therapy, this is a general reflection of first salvage therapies. The outcome of patients undergoing second salvage therapy in relation to complete response (CR) rates and survival has not been documented. The authors analyzed the outcome of patients with AML undergoing second salvage therapy, and identified prognostic factors associated with response and survival. The records of 594 patients with AML undergoing second salvage therapy from 1980 until 2004 were reviewed. The patient median age was 50 years. Salvage therapy included allogeneic stem cell transplantation (SCT) in 74 patients, standard-dose cytosine arabinoside (ara-C) combinations in 30 patients, high-dose ara-C combinations in 171 patients, non-ara-C combinations in 73 patients, and Phase I-II single agents in 246 patients. Overall, 76 patients (13%) achieved CR. The median CR duration was 7 months. The median survival was 1.5 months, and the 1-year survival rate was 8%. A multivariate analysis of prognostic factors for CR identified the following 6 independent adverse factors: first CR duration < 6 months; second CR duration < 6 months; sa...Continue Reading


Jan 11, 1992·Leukemia·M E Nesbit, W G Woods
Aug 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J KeatingE J Freireich
Nov 26, 2002·Hematology·Francis J GilesHagop M Kantarjian
Jan 1, 1991·Leukemia & Lymphoma·L AngelovA Keating

❮ Previous
Next ❯


Oct 8, 2011·Current Hematologic Malignancy Reports·E J Feldman, Usama Gergis
Nov 8, 2012·International Journal of Hematology·Brian McLaughlinMichael Boyiadzis
May 26, 2009·Journal of Hematology & Oncology·Karen SeiterNasir Ahmed
Dec 4, 2012·Mediterranean Journal of Hematology and Infectious Diseases·Saveria CapriaGiovanna Meloni
Aug 2, 2013·Future Oncology·Courtney D DiNardoFarhad Ravandi
Dec 17, 2009·Leukemia & Lymphoma·Stefan Faderl
Feb 28, 2007·Leukemia & Lymphoma·Bruno C MedeirosJoseph M Brandwein
Nov 2, 2011·Expert Opinion on Investigational Drugs·Aine Carol Burke, Frank James Giles
Apr 22, 2011·American Journal of Hematology·Farshid DayyaniGuillermo Garcia-Manero
Jun 19, 2012·British Journal of Haematology·Susan O'BrienFrancis J Giles
Jul 4, 2007·Hematology·Ronan SwordsFrancis Giles
May 29, 2015·American Journal of Hematology·Courtney D DiNardoHagop Kantarjian
Mar 19, 2014·Clinical Lymphoma, Myeloma & Leukemia·Apostolia Maria TsimberidouGautam Borthakur
Nov 9, 2011·Clinical Lymphoma, Myeloma & Leukemia·Farhad Ravandi
Dec 12, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Simrit ParmarSergio Giralt
Jan 13, 2015·Current Opinion in Hematology·Robert J OrlowskiSelina M Luger
May 21, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gail J RobozFrancis J Giles
Dec 6, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gail J RobozEric J Feldman
Dec 4, 2014·Therapeutic Advances in Hematology·Lindsay A M Rein, David A Rizzieri
Sep 21, 2018·Leukemia & Lymphoma·Christine M McMahon, Alexander E Perl
Apr 1, 2015·The Journal of Cell Biology·Devinderjit K MoudgilGordon K T Chan
Jun 11, 2020·Blood·Susan DeWolf, Martin S Tallman
Nov 10, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Francis GilesHagop Kantarjian
Aug 15, 2020·Clinical Lymphoma, Myeloma & Leukemia·Farhad RavandiHagop Kantarjian

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.